Retraction: Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells (Proceedings of the National Academy of Sciences of the United States of America (2009) 106 (2353-2358) DOI: 10.1073/pnas.0812801106);Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 7, 2009, Pages 2353-2358

  Lee, KangAe ^a   Qian, David Z ^a   Rey, Sergio ^a   Wei, Hong ^a   Liu, Jun O ^a   Semenza, Gregg L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Broadway Research Building   (United States)

Author keywords

Adriamycin; Endothelial progenitor cells; Hepatocellular carcinoma; Hypoxia; Xenograft

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; ENDOTHELIAL CELL GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSCRIPTION INITIATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

MUS;

EID: 60549092506     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.2213285119     Document Type: Erratum

References (26)

1. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. J Mol Med 26:225-239.
2. Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12:853-859.
3. Forsythe JA, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613.
4. Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230-1237.
5. Kaelin WG, Jr, Ratcliffe PJ (2008) Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 30:393-402.
6. Peet DJ, et al. (2004) Oxygen-dependent asparagine hydroxylation. Methods Enzymol 381:467-487.
7. Semenza GL, et al. (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271:32529-32537.
8. Vergis R, et al. (2008) Intrinsic markers of tumor hypoxia and angiogenesis in localized prostate cancer and outcome of radical treatment: A retrospective analysis of two randomized radiotherapy trials and one surgical cohort study. Lancet Oncol 9:342-351.
9. Xie H, et al. (2008) The expression of hypoxia-inducible factor-1α in hepatitis B virus-related hepatocellular carcinoma: Correlation with patients' prognosis and hepatitis B virus X protein. Dig Dis Sci 53:3225-3233.
10. Melillo G (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26:341-352.
11. Chong CR, et al. (2007) Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2:263-270.
12. Jiang B-H, et al. (1997) Transactivation and inhibitory domains of hypoxia-inducible factor 1α: Modulation of transcriptional activity by oxygen tension. J Biol Chem 272:19253-19260.
13. Chaires JB, Herrera JE, Waring MJ (1990) Preferential binding of daunomycin to 5′ATCG and 5′ATGC sequences revealed by footprinting titration experiments. Biochemistry 29:6145-6153.
14. Priebe W, et al. (2001) Exploiting anthracycline scaffold for designing DNA-targeting agents. Methods Enzymol 340:529-555.
15. Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2:188-200.
16. Quesada AJ, et al. (2005) In vivo up-regulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metromomic doxorubicin treatment. Cell Death Differ 12:649-658.
17. Ceradini DJ, et al. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858-864.
18. Du R, et al. (2008) HIF-1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-220.
19. Drevs J, et al. (2004) Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24:1759-1763.
20. Yamazaki Y, et al. (2006) Anthracyclines, small-molecule inhibitors of hypoxia-inducible factor-1α activation. Biol Pharm Bull 29:1999-2003.
21. Duyndam MC, et al. (2007) Cisplatin and doxorubicin repress vascular endothelial growth factor expression and differentially down-regulate hypoxia-inducible factor 1 activity in human ovarian cancer cells. Biochem Pharmacol 74:191-201.
22. Kim Y, et al. (2003) Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63:368-377.
23. Szulawska A, Gniazdowski M, Czyz M (2005) Sequence specificity of formaldehyde-mediated covalent binding of anthracycline derivatives to DNA. Biochem Pharmacol 69:7-18.
24. Mansilla S, Portugal J (2008) Sp1 transcription factor as a target for anthracyclines: Effects on gene transcription. Biochimie 90:976-987.
25. Bosch-Marce M, et al. (2007) Effects of aging and hypoxia-inducible factor 1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 101:1310-1318.
26. Baek JH, et al. (2007) Spermidine/spermine-N1-acetyltransferase 2 is an essential component of the ubiquitin ligase complex that regulates hypoxia-inducible factor 1α. J Biol Chem 282:23572-23580.